Sami-Sabinsa’s Biotech site achieves USP GMP audited status
USP’s GMP audit program helps dietary ingredient manufacturers ensure compliance with GMP requirements
The Sami-Sabinsa Group’s Nelamangala biotechnology site in Bengaluru, India has been audited by the United States Pharmacopeia (USP) and received a GMP compliance certificate on February 25, 2019.
The certificate recognizes that the site operates GMP quality systems which meet the requirements set forth in 21 CFR Part 117 Current Good Manufacturing Practice, Hazard Analysis and Risk-Based Preventive Controls for Human Food, and USP-NF General Chapter <2750> Manufacturing Practices for Dietary Supplements for Dietary Ingredient Manufacturing.
